Study of ACE2 gene expression and evaluated some cellular and humoral immunity parameters of COVID-19 patients in Ramadi City

Ibraheem A. Shabeeb; Mohammed J. Mansoor Al-Taee; Mohamed B. Al-jobory

doi:10.53730/ijhs.v6nS5.9185

Authors

Ibraheem A. Shabeeb College of Science, University of Anbar, Iraq
Mohammed J. Mansoor Al-Taee Quality Control Department, Anbar Province, Iraq
Mohamed B. Al-jobory National Center for Occupational Health and Safety, Anbar Province, Iraq

Keywords:

COVID-19, SARS-CoV-2, IL-6, IL-10, TNF-α, NBT, ACE2, RT-PCR

Abstract

The new coronavirus SARS-CoV-2 is responsible for the COVID-19 epidemic. SARS-CoV-2 accesses host cells by ACE2, which is abundantly expressed in the heart, kidneys, and lungs and shed into the plasma. Many SARS-CoV-2 patients' neutralizing antibody titers and memory B cell responses may be transient, exposing them to re-infection. Notably, neutralizing antibody titers and the number of virus-specific T cells had a substantial relationship. Our findings lay the groundwork for additional research into protective immunity against SARS-CoV-2 and the etiology of COVID-19, particularly in severe instances. The most important characteristic of our findings a positive correlation between all parameters (cellular and humoral) and COVID-19 patients compared with healthy group excepting neutrophil cells where no significant difference was observed between the two groups. Lymphopenia and elevated levels of specific cytokines, such as IL-6, IL-10, and TNF-α, have been linked to illness severity in general. T cells are thought to play a key role in the first immune response. In extreme situations, a significant drop in T cell counts is virtually always detected.

Downloads

Download data is not yet available.

References

Wang, C., Horby, P.W., Hayden, F.G., and Gao, G.F. (2020). A novel coronavirus outbreak of global health concern. Lancet 395, 470–473.

Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565–574.

Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020, 130, 2620–2629.

Phelan, A.L., Katz, R., and Gostin, L.O. (2020). The Novel Coronavirus Originating in Wuhan (China: Challenges for Global Health Governance. JAMA).

Di Pierro, F., Bertuccioli, A., and Cavecchia, I. (2020). Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus. Minerva Gastroenterol. Dietol. Published online March 12, 2020.

Koh, D.; Sng, J. Lessons From the Past: Perspectives on Severe Acute Respiratory Syndrome. Asia Pac. J. Public Health 2010, 22, 132S–136S.

Liu, D.X.; Liang, J.Q.; Fung, T.S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1. Ref. Module. Life Sci. 2020.

Lipsitch, M. Estimating case fatality rates of COVID-19. Lancet. Infect. Dis. 2020, 20, 775.

Paules, C.I.; Marston, H.D.; Fauci, A.S. Coronavirus Infections—More Than Just the Common Cold. JAMA 2020, 323, 707–708.

Yin, Y.; Wunderink, R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirol. Carlton Vic.2018, 23, 130–137.

Srinivasan, S.; Cui, H.; Gao, Z.; Liu, M.; Lu, S.; Mkandawire, W.; Narykov, O.; Sun, M.; Korkin, D. Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins.Viruses 2020, 12, 360.

Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020.

Kikkert, M. Innate Immune Evasion by Human Respiratory RNA Viruses. J. Innate Immun. 2020, 12, 4–20.

Tas, S. K., Kirkik, D., Işik, M. E., Kalkanli, N., Uzunoglu, A. S., Uzunoglu, M. S. & Tanoglu, A. (2020). Role of ACE2 Gene Expression in Renin Angiotensin System and Its Importance in Covid-19: In Silico Approach. Brazilian Archives of Biology and Technology, 63.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol.2004;203:2:631-7. Doi: 10.1002/path.1570

Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J et al. Human intestine luminalACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids.2015;47:693–705. Doi:1007/s00726-014-1889-6

Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008;51(4):613-23. Doi:10.1053/j.ajkd.2007.11.022.

Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004 May 19;2:19. Doi:10.1186/1741-7015-2-19.

Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020. doi:10.1101/2020.01.26.919985

Christiaansen, A.; Varga, S.M.; Spencer, J.V. Viral manipulation of the host immune response. Curr. Opin. Immunol. 2015, 36, 54–60.

Chen, Y.; Tong, X.; Li, Y.; Gu, B.; Yan, J.; Liu, Y.; Shen, H.; Huang, R.; Wu, C. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020, 16, e1008796. [CrossRef] [PubMed]

Ye, X.; Xiao, X.; Li, B.; Zhu, W.; Li, Y.; Wu, J.; Huang, X.; Jin, J.; Chen, D.; Jin, J.; et al. Low Humoral Immune Response and Ine_ective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up. Front. Oncol. 2020, 10, 1272. [CrossRef] [PubMed]

Beyerstedt, S., Casaro, E. B., & Rangel, É. B. (2021). COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European Journal of Clinical Microbiology & Infectious Diseases, 1-15.

Chen, C., Boorla, V. S., Banerjee, D., Chowdhury, R., Cavener, V. S., Nissly, R. H. & Maranas, C. D. (2021). Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. Proceedings of the National Academy of Sciences, 118(42).

Lamm, N., Read, M. N., Nobis, M., Van Ly, D., Page, S. G., Masamsetti, V. P., and Cesare, A. J. (2020). Nuclear F-actin counteracts nuclear deformation and promotes fork repair during replication stress. Nature Cell Biology, 22(12), 1460-1470.

Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods, 25(4), 402-408.

Yamamoto, T., Kihara, I., Hara, M., Yaoita, E., & Kawasaki, K. (1983). Nitroblue tetrazolium (NBT) reduction by polymorphonuclear leukocytes on contact with immune complexes in renal glomeruli. The Japanese journal of experimental medicine, 53(6), 275-280.‏

Chen C, Zhang XR, Ju ZY, He WF. (2020) Advances in the research of cytokine storm mechanism induced by Corona virus disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi.; 36(0):E005.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, and Manson JJ. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 395(10229):1033–4. https://doi.org/10.1016/S0140-6736 (20)30628-0.

Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, (2020). Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J.; 133(9):1025–31. https://doi.org/10.1097/CM9.0000000000000744.

Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, (2020). Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jie He He Hu Xi Za Zhi.; 43(3):215–8.

Zhu, B., Feng, X., Jiang, C., Mi, S., Yang, L., Zhao, Z., & Zhang, L. (2021). Correlation between white blood cell count at admission and mortality in COVID-19 patients: a retrospective study. BMC Infectious Diseases, 21(1), 1-5.

Selim, S. (2020). Leukocyte count in COVID-19: an important consideration. The Egyptian Journal of Bronchology, 14(1), 1-2.

Lee, J., Park, S. S., Kim, T. Y., Lee, D. G., & Kim, D. W. (2021). Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study. Cancers, 13(3), 471.

Tan, L.; Wang, Q.; Zhang, D.; Ding, J.; Huang, Q.; Tang, Y.Q.; Wang, Q.; Miao, H. (2020). Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal. Transduct. Target. Ther., 5, 33.

Zhang, C.; Wang, X.M.; Li, S.R.; Twelkmeyer, T.; Wang, W.H.; Zhang, S.Y.; Wang, S.F.; Chen, J.Z.; Jin, X.; Wu, Y.Z.; (2021). NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat. Commun., 10, 1507. [CrossRef] Cancers, 13, 471 15 of 15 30.

Zheng, H.Y.; Zhang, M.; Yang, C.X.; Zhang, N.; Wang, X.C.; Yang, X.P.; Dong, X.Q.; Zheng, Y.T. (2020). Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol. Immunol., 17, 541–543. [CrossRef]

Hellum, K. B. (1977). Nitroblue tetrazolium test in bacterial and viral infections. Scandinavian journal of infectious diseases, 9(4), 269-276.

Chen X., Zhao B., Qu Y., Chen Y., Xiong J., Feng J. (2020). Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) levels in critically ill COVID-19 patients. bioRxiv. doi: 10.1101/2020.02.29.20029520. [PMC free article] [PubMed] [CrossRef] [Google Scholar].

Wang H., Luo S., Shen Y., Li M., Zhang Z., Dong Y. (2020). Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score. SSRN. doi: 10.2139/ssrn.3544837. [CrossRef] [Google Scholar] [Ref list]

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506.10.1016/S0140-6736(20)30183-5.

Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. . Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. (2020) 7:1003–11. 10.1093/nsr/nwaa037

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. . Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. (2020) 71:762–68. 10.1093/cid/ciaa248

McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. (2020) 202:812–21. 10.1164/rccm.202005-1583OC

Feldmann M., Maini R.N., Woody J.N. (2020). Trials of anti-tumor necrosis factor therapy for COVID-19 are urgently needed. Lancet.; 395: 1407–1409. [PMC free article] [PubMed] [Google Scholar] [Ref list]

Annoni, F., Orbegozo, D., Rahmania, L., (2019). Angiotensin-converting enzymes in acute respiratory distress syndrome. Intensive Care Med. 45, 1159–1160.

Bao, L., Deng, W., Huang, B., (2020). The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature Online ahead of print.

Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, Muench MO, Simmons G, Hofmann H, Kuri T, Weber F, Eichler J, Drosten C, Pöhlmann S (2010) Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. Journal of Virology 84:1198

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324: 782–793.

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. (2020). High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 12: 1–5.

Tikellis C, Bernardi S, Burns WC (2011) Angiotensin-converting enzyme 2 is a key modulator of the renin–angiotensin system in cardiovascular and renal disease. Current Opinion in Nephrology and Hypertension 20:62–68

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949